Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New hope for sickle cell patients: drug combo may prevent transplant failure

NCT ID NCT07252050

First seen Nov 26, 2025 · Last updated May 25, 2026 · Updated 20 times

Summary

This study tests whether adding the drug ruxolitinib to a standard stem cell transplant can lower the chance of graft failure in children and young adults (ages 12-45) with severe sickle cell disease. About 24 participants will receive the treatment and be followed for 2 years. The goal is to improve survival without needing a second transplant or facing other serious complications.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEMATOPOETIC STEM CELL TRANSPLANT are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Children's Healthcare of Atlanta

    RECRUITING

    Atlanta, Georgia, 30329, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Children's Hospital of Colorado

    NOT_YET_RECRUITING

    Aurora, Colorado, 80045, United States

    Contact

  • Children's Hospital of Philadelphia

    NOT_YET_RECRUITING

    Philadelphia, Pennsylvania, 19104, United States

    Contact

  • Manning Family Children's

    NOT_YET_RECRUITING

    New Orleans, Louisiana, 70118, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.